Bavdegalutamide

DB19032InvestigationalSmall molecule

Bavdegalutamide is under investigation in clinical trial NCT03888612 (Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer).

Mechanism: Pharmacologically active on Androgen receptor
Curator reviewed
Formula / weight: C₄₁H₄₃ClFN₉O₆ · 812.3 g/mol (avg)
Also known as: 3-pyridazinecarboxamide, n-(trans-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6-(4-((4-(2-(2,6-dioxo-3-piperidinyl)-6-fluoro-2,3-dihydro-1,3-dioxo-1h-isoindol-5-yl)-1-piperazinyl)methyl)-1-piperidinyl)- · Arv-110 (protac) · N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxo-2,3-dihydro-1h-isoindol-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3-carboxamide
Code names: ARV-110

Resolves to

Compound

UNIIH6NYM0V650CAS2222112-77-6ChEMBLCHEMBL4862963

Structure

InChIKeyCLCTZVRHDOAUGJ-SYVGMNBRSA-NSMILES

FC1=CC2=C(C=C1N1CCN(CC3CCN(CC3)C3=CC=C(N=N3)C(=O)N[C@H]3CC[C@@H](CC3)OC3=CC=C(C#N)C(Cl)=C3)CC1)C(=O)N(C1CCC(=O)NC1=O)C2=O

Targets

P10275AR

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Bavdegalutamide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account